The impact of stroma components on angiogenesis and Cancer Stem Cell (CSC) biology as a critical step in overcoming drug resistance is studied in WP3 using genetically engineered mouse models of pancreatic cancer (e.g. Hingorani et al 2003, Hingorani et al 2005, Guerra et al 2007) and xenografted human primary cancers (Sorio et al 2001). From a therapeutic perspective, WP3 elucidates the role of the inflammatory stroma in mediating resistance to anti-angiogenic and anti-proliferative pharmacological strategies and identifies potential therapeutic routes to target the inflammatory stroma to overcome drug resistance. Additionally, the role of CSCs in the progression of pancreatic cancer and resistance to therapeutics will be established, in order to identify new therapeutic vulnerabilities of CSCs.

WP lead:

Cancer Research UK, United Kingdom (CR-UK)

WP members:

Philipps-Universität Marburg, Germany (UNIMAR)
The University of Liverpool, United Kingdom (ULIV) per Participant
Fundación Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO)
University of Verona, Italy (UNIVR)
Ernst-Moritz-Arndt-Universität Greifswald, Germany (EMAU-G)
Karolinska Institute, Sweden (KI)
Technische Universität München, Klinikum rechts der Isar, Germany (TUM-MED)
Bayer Schering Healthcare, Germany (BSP)